A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in early detection of ocular toxicity from hydroxychloroquine

International Ophthalmology

Volumn 31, Issue 4, 2011, Pages 283-289

  Heravian, Javad ^a   Saghafi, Massoud ^b   Shoeibi, Naser ^c   Hassanzadeh, Samira ^a   Shakeri, Mohammad Taghi ^a   Sharepoor, Maria ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Color vision; Hydroxychloroquine; Perimetery; Photostress recovery time; Rheumatoid arthritis; Systemic lupus erythematosus; Visual evoked potential

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; ARTICLE; COLOR VISION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; EVOKED VISUAL RESPONSE; EYE TOXICITY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; PERIMETRY; PHOTOSTRESS RECOVERY TIME; RETINA MACULOPATHY; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL ACUITY; VISUAL FIELD; VISUAL SYSTEM PARAMETERS;

ADULT; ANTIRHEUMATIC AGENTS; COLOR VISION; EARLY DIAGNOSIS; EVOKED POTENTIALS, VISUAL; EYE DISEASES; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; PROGNOSIS; RHEUMATIC DISEASES; RISK FACTORS; VISION TESTS; VISUAL FIELDS; YOUNG ADULT;

EID: 80054733581     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-011-9456-6     Document Type: Article

References (22)

1. HS Weisinger K Pesudovs HB Collin 2000 Management of patients undergoing hydroxychloroquine (Plaquenil) therapy Clin Exp Optom 83 32 36 12472464 10.1111/j.1444-0938.2000.tb05072.x
2. RK Maturi M Yu RG Weleber 2004 Multifocal electroretinographic evaluation of long-term hydroxychloroquine users Arch Ophthalmol 122 973 981 15249360 10.1001/archopht.122.7.973 1:CAS:528:DC%2BD2cXmtl2rtLs%3D
3. DJ Browning 2002 Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity Am J Ophthalmol 133 649 656 11992862 10.1016/S0002-9394(02)01392-2 1:CAS:528:DC%2BD38Xjt1Sgsb8%3D
4. MF Marmor RE Carr M Easterbrook AA Farjo WF Mieler 2002 Recommendations on screening for chloroquine and hydroxychloroquine retinopathy Ophthalmology 109 1377 1382 12093666 10.1016/S0161-6420(02)01168-5
5. A Bidari M Soltan Sanjari MA Saba M Ahmadi 2003 Determination of chloroqiene retinal toxicity on perimetric findings in 52 rheumatoid arthritis patients with normal funduscopic findings J Iran Med University 11 41 392 396
6. FC Arnett SM Edwerthy DA Bloch, et al. 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315 324 3358796 10.1002/art.1780310302 1:STN:280: DyaL1c7pt1Ohsg%3D%3D
7. MC Hochberg 1997 Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 40 17 25 10.1002/art.1780400928
8. JV Odom M Bach C Barber M Brigell, et al. 2004 Visual evoked potentials standard (2004) Doc Ophthalmol 108 115 123 15455794 10.1023/B:DOOP.0000036790. 67234.22
9. JC Yam AK Kwok 2006 Ocular toxicity of hydroxychloroquine Hong Kong Med J 12 294 304 16912357 1:STN:280:DC%2BD28voslKhuw%3D%3D
10. TH Margrain D Thomson 2002 Sources of variability in the clinical photo stress test Ophthalmic Physiol Opt 22 61 67 11824648 10.1046/j.1475-1313.2002. 00005.x
11. RE Carr P Henkind N Rothfield IM Siegel 1968 Ocular toxicity of antimalarial drugs long term follow-up Am J Ophthalmol 66 738 744 5729592 1:STN:280:DyaF1M3htVCktw%3D%3D
12. M Easterbrook 1993 The ocular safety of hydroxychloroquine Semin Arthritis Rheum 23 Suppl 1 62S 67S 10.1016/S0049-0172(10)80009-5
13. Anyanwu EC, Kanu I, Nnadozie JB. Electrophysiological evaluation of adolescents presenting with chloroquine toxicity due to persistent malaria infections. Internet J Neurol 2006; 5 (2)
14. MK Eman K Tayseer MF Hassan A Gamal AS Esam 2001 Multimodal electroneurophysiological studies of systemic lupus erythematosus Neuropsychobiology 43 204 212 10.1159/000054891
15. PR Bartel P Roux 1994 Visual function and long-term chloroquine treatment S Afr Med J 84 32 34 8197491 1:STN:280:DyaK2c3lsFyjtg%3D%3D
16. BL Vu M Easterbrook JK Hovis 1999 Detection of color vision defects in chloroquine retinopathy Ophthalmology 106 1799 1804 10485553 10.1016/S0161-6420(99)90338-X 1:STN:280:DyaK1MvhtlGlsQ%3D%3D
17. M Easterbrook 1988 Ocular effects and safety of antimalarial agents Am J Med 85 23 29 3177429 10.1016/0002-9343(88)90358-0 1:STN:280: DyaL1M%2Fitlajug%3D%3D
18. SK Shinjo WA Tizzianni 2007 Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration? Clin Rheumatol 26 1248 1253 17264974 10.1007/s10067-006-0478-9
19. M Elder MA Anmar 2006 Early paracentral visual field loss in patients taking hydroxychloroquine Arch Ophthalmol 124 1729 1733 17159032 10.1001/archopht.124.12.1729
20. P Grutzner 1969 Acquired color vision defects secondary to retinal drug toxicity Ophthalmologica 158 suppl 592 604 5307973
21. MR Razeghinejad F Torkaman H Amini 2005 Blue-yellow perimetery can be an early detector of chloroquine and hydroxychloroquine retinopathy Med Hypothesis 65 629 630 10.1016/j.mehy.2005.04.005 1:CAS:528:DC%2BD2MXlvFyntb4%3D
22. R Tzecov 2005 Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates Doc Ophthalmol 110 111 120 10.1007/s10633-005-7349-6